Arcutis Biotherapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Arcutis Biotherapeutics wird ein jährliches Gewinn- und Umsatzwachstum von 66.3% bzw. 36% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 67.8% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich -66.7% betragen.

Wichtige Informationen

66.3%

Wachstumsrate der Gewinne

67.8%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	24.5%
Wachstumsrate der Einnahmen	36.0%
Zukünftige Eigenkapitalrendite	-66.7%
Analystenabdeckung	Good
Zuletzt aktualisiert	20 May 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported Yearly Earnings And Analysts Are Lifting Their Estimates

Mar 02

Recent updates

Analysts' Revenue Estimates For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Are Surging Higher

May 24

Arcutis Stock: Sales Expansion Momentum Puts It On A Good Trajectory

May 20

Arcutis Biotherapeutics: Betting Big On Zoryve

May 01

New Forecasts: Here's What Analysts Think The Future Holds For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)

Apr 25

Need To Know: Analysts Are Much More Bullish On Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenues

Mar 03

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported Yearly Earnings And Analysts Are Lifting Their Estimates

Mar 02

Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) 75% Share Price Surge Not Quite Adding Up

Feb 28

Arcutis: Slow Sales Of Zoryve May Be Painting The Wrong Picture

Jan 31

Growth Investors: Industry Analysts Just Upgraded Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenue Forecasts By 21%

Oct 23

Analysts' Revenue Estimates For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Are Surging Higher

Aug 13

Earnings Release: Here's Why Analysts Cut Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Price Target To US$41.57

Aug 11

Does Arcutis Biotherapeutics (NASDAQ:ARQT) Have A Healthy Balance Sheet?

May 02

Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment?

Dec 18

Arcutis sees positive top-line results from roflumilast in scalp and body psoriasis

Sep 26

Arcutis Biotherapeutics: A Name To Accumulate

Sep 18

Arcutis acquires privately-held biotech Ducentis BioTherapeutics

Sep 07

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:ARQT - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	399	-8	86	N/A	7
12/31/2025	246	-139	-72	N/A	7
12/31/2024	164	-191	-128	N/A	6
3/31/2024	106	-217	-199	-198	N/A
12/31/2023	60	-262	-247	-247	N/A
9/30/2023	49	-268	-262	-262	N/A
6/30/2023	11	-331	-309	-286	N/A
3/31/2023	6	-327	-304	-281	N/A
12/31/2022	4	-311	-281	-258	N/A
9/30/2022	1	-311	-262	-238	N/A
6/30/2022	N/A	-260	-212	-212	N/A
3/31/2022	N/A	-235	-186	-185	N/A
12/31/2021	N/A	-206	-176	-175	N/A
9/30/2021	N/A	-169	-156	-155	N/A
6/30/2021	N/A	-150	-149	-148	N/A
3/31/2021	N/A	-144	-139	-138	N/A
12/31/2020	N/A	-136	-113	-113	N/A
9/30/2020	N/A	-114	-97	-97	N/A
6/30/2020	N/A	-90	-74	-74	N/A
3/31/2020	N/A	-63	-57	-57	N/A
12/31/2019	N/A	-42	-43	-43	N/A
9/30/2019	N/A	-35	-32	-32	N/A
6/30/2019	N/A	-28	-24	-24	N/A
3/31/2019	N/A	-23	-19	-18	N/A
12/31/2018	N/A	-19	-14	-14	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: ARQT wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (2.4%).

Ertrag vs. Markt: ARQT wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: ARQT wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: ARQTDie Einnahmen des Unternehmens (36% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.7% pro Jahr).

Hohe Wachstumseinnahmen: ARQTDie Einnahmen des Unternehmens (36% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: ARQT wird voraussichtlich in 3 Jahren unrentabel sein.

Arcutis Biotherapeutics Zukünftiges Wachstum

Future Kriterienprüfungen 5/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Consensus revenue estimates increase by 36%

Consensus revenue estimates increase by 10%

Consensus revenue estimates increase by 24%

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported Yearly Earnings And Analysts Are Lifting Their Estimates

Price target increased by 18% to US$13.33

Consensus revenue estimates increase by 19%

Recent updates

Senior VP & Chief Medical Officer exercised options and sold US$201k worth of stock

Senior VP & Chief Medical Officer recently sold US$435k worth of stock

Senior VP & Chief Medical Officer notifies of intention to sell stock

Analysts' Revenue Estimates For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Are Surging Higher

Consensus revenue estimates increase by 36%

Arcutis Stock: Sales Expansion Momentum Puts It On A Good Trajectory

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Arcutis Biotherapeutics, Inc. Announces Journal of Clinical and Aesthetic Dermatology Publishes the Outcomes of a Comprehensive Evaluation by an Expert Dermatology

President notifies of intention to sell stock

Arcutis Biotherapeutics: Betting Big On Zoryve

Arcutis Biotherapeutics, Inc. to Report Q1, 2024 Results on May 14, 2024

Arcutis Biotherapeutics, Inc., Annual General Meeting, Jun 14, 2024

New Forecasts: Here's What Analysts Think The Future Holds For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)

Consensus revenue estimates increase by 10%

Arcutis Biotherapeutics, Inc. Announces Chief Financial Officer Changes

Arcutis Presents Late-Breaking Data from INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 At the American Academy of Dermatology Annual Meeting

President notifies of intention to sell stock

Consensus revenue estimates increase by 24%

Need To Know: Analysts Are Much More Bullish On Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenues

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Just Reported Yearly Earnings And Analysts Are Lifting Their Estimates

Arcutis Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $150.000003 million.

Arcutis Biotherapeutics, Inc.'s (NASDAQ:ARQT) 75% Share Price Surge Not Quite Adding Up

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Price target increased by 18% to US$13.33

Arcutis Biotherapeutics, Inc. to Report Q4, 2023 Results on Feb 27, 2024

Arcutis Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Arcutis: Slow Sales Of Zoryve May Be Painting The Wrong Picture

Arcutis Biotherapeutics, Inc. Announces New Subgroup Analysis Highlighting That Adults and Adopts ZoryVE Topical Foam, 0.3% Clears Seborrheic Dermatitis in Individuals Who Previously Reported an Inadequate Response to Topical Steroids

Arcutis Biotherapeutics, Inc. Announces New Individual Patient Response Data Showed at the 2024 Winter Clinical Dermatology Conference - Hawaii

FDA Approves Arcutis' ZORYVE®? (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older

President exercised options to buy US$118k worth of stock.

Arcutis Biotherapeutics, Inc. Announces FDA Accepts Supplemental New Drug Application for Roflumilast Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to Age 6

Consensus revenue estimates increase by 19%

Growth Investors: Industry Analysts Just Upgraded Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Revenue Forecasts By 21%

New major risk - Shareholder dilution

Arcutis Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $99.99925 million.

New major risk - Revenue and earnings growth

Consensus revenue estimates increase by 10%

Arcutis Biotherapeutics, Inc. Presents Positive Patient-Reported Outcome Data from the Pivotal Arrector Phase 3 Trial in Scalp and Body Psoriasis At European Academy of Dermatology and Venereology (Eadv) Congress

Price target decreased by 14% to US$37.86

Arcutis Biotherapeutics, Inc. Announces FDA Approves ZORYVE (Roflumilast) Cream 0.3% for Treatment of Psoriasis in Children Ages 6 to 11

Arcutis Biotherapeutics, Inc. Announces Executive Changes

Arcutis Announces Positive Long-Term Results of Roflumilast Cream 0.15% Showing Durable and Improved Efficacy over Time and Favorable Safety Profile in Treatment of Mild to Moderate Atopic Dermatitis (Ad)

Arcutis Biotherapeutics, Inc. Announces Chief Financial Officer Changes, Effective August 31, 2023

Consensus revenue estimates increase by 26%

Analysts' Revenue Estimates For Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Are Surging Higher

Earnings Release: Here's Why Analysts Cut Their Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Price Target To US$41.57

New minor risk - Financial position

Price target decreased by 8.5% to US$41.71

Arcutis Biotherapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Arcutis Announces Zoryve® (Roflumilast) Cream 0.3% Included in Preferred Position on National Formularies for CVS Caremark

Arcutis Biotherapeutics, Inc. Announces Executive Changes

Price target decreased by 9.2% to US$45.50

Does Arcutis Biotherapeutics (NASDAQ:ARQT) Have A Healthy Balance Sheet?

Director exercised options and sold US$104k worth of stock

Director exercised options and sold US$88k worth of stock

Director exercised options and sold US$130k worth of stock

Arcutis Biotherapeutics, Inc. to Report Q4, 2022 Results on Feb 28, 2023

Director exercised options and sold US$102k worth of stock

Forecast to breakeven in 2025

Arcutis Biotherapeutics, Inc. Submits Supplemental New Drug Application for ZORYVE Cream 0.3% for Expanded Indication for the Treatment of Plaque Psoriasis in Children Down to 2 Years of Age

Is Arcutis Biotherapeutics (NASDAQ:ARQT) A Risky Investment?

Arcutis Biotherapeutics, Inc. Announces Positive Topline Results from Second Atopic Dermatitis Pivotal Phase 3 Trial of Roflumilast Cream in Adults and Children Aged 6 and Older

Arcutis Biotherapeutics, Inc. Enrolls First Patient in Phase 1B Alopecia Areata Study Evaluating ARQ-255

Arcutis Biotherapeutics, Inc. Announces the Publication of Positive Patient-Reported Outcome Itch Data from Its Phase 2B Study Evaluating Once-Daily Roflumilast Cream (0.3% and 0.15%) in Adults with Chronic Plaque Psoriasis

Arcutis’ ZORYVE® (Roflumilast) Cream 0.3% Added to Express Scripts, Inc.® National Formularies in the United States

Arcutis Biotherapeutics, Inc. Announces Positive Topline Results from INTEGUMENT-1 Pivotal Phase 3 Trial of Roflumilast Cream

Consensus forecasts updated

Arcutis Biotherapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022